Study of ARO-MUC5AC in Healthy Subjects and Patients With Asthma
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
of ARO-MUC5AC in normal healthy volunteers (NHVs) and in patients with moderate to severe
asthma. In part 1 NHVs will receive a single dose of ARO-MUC5AC or placebo. In part 2 of the
study, NHVs and adult patients with asthma will receive 3 doses of ARO-MUC5AC or placebo.